138 related articles for article (PubMed ID: 26056491)
21. Comparison of change in body weight between contraception containing 30-μg ethinylestradiol/2-mg chlormadinone acetate or 30-μg ethinylestradiol/3-mg drospirenone: a randomised controlled trial.
Wongwananuruk T; Panichyawat N; Panchalee T; Jirakittidul P; Angsuwathana S; Sirimai K; Thamkhantho M; Chiravacharadej G
Eur J Contracept Reprod Health Care; 2020 Feb; 25(1):43-48. PubMed ID: 31756117
[No Abstract] [Full Text] [Related]
22. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
Anttila L; Kunz M; Marr J
Contraception; 2009 Nov; 80(5):445-51. PubMed ID: 19835718
[TBL] [Abstract][Full Text] [Related]
23. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism.
Gaspard U; Scheen A; Endrikat J; Buicu C; Lefebvre P; Gerlinger C; Heithecker R
Contraception; 2003 Jun; 67(6):423-9. PubMed ID: 12814810
[TBL] [Abstract][Full Text] [Related]
24. A clinical overview of a new triphasic contraceptive containing gestodene.
Christie T
Int J Fertil; 1989 Sep; 34 Suppl():40-9. PubMed ID: 2576257
[TBL] [Abstract][Full Text] [Related]
25. Adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study.
Wiegratz I; Elliesen J; Paoletti AM; Walzer A; Kirsch B
Int J Womens Health; 2015; 7():19-29. PubMed ID: 25609999
[TBL] [Abstract][Full Text] [Related]
26. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers.
Blode H; Wuttke W; Loock W; Röll G; Heithecker R
Eur J Contracept Reprod Health Care; 2000 Dec; 5(4):256-64. PubMed ID: 11245553
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone.
Huber J; Foidart JM; Wuttke W; Merki-Feld GS; The HS; Gerlinger C; Schellschmidt I; Heithecker R
Eur J Contracept Reprod Health Care; 2000 Mar; 5(1):25-34. PubMed ID: 10836660
[TBL] [Abstract][Full Text] [Related]
28. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
Boschitsch E; Skarabis H; Wuttke W; Heithecker R
Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
[TBL] [Abstract][Full Text] [Related]
29. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
van Heusden AM; Fauser BC
Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of the contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive in Chinese women: a 1-year randomised trial.
Fan GS; Ren M; Di W; Su P; Chang Q; Wu S; Qin Y; Korver T; Marintcheva-Petrova M; Yacik C; McCrary Sisk C; Wang G
Eur J Contracept Reprod Health Care; 2016 Aug; 21(4):303-9. PubMed ID: 27339759
[TBL] [Abstract][Full Text] [Related]
31. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen.
Marr J; Niknian M; Shulman LP; Lynen R
Contraception; 2011 Jul; 84(1):81-6. PubMed ID: 21664515
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol.
Kroll R; Ackerman R; Feldman R; Howard B; Weiss H; Hsieh J; Ricciotti N
Contraception; 2016 Mar; 93(3):249-56. PubMed ID: 26499407
[TBL] [Abstract][Full Text] [Related]
33. Bleeding Pattern and Management of Unexpected Bleeding/Spotting with an Extended Regimen of a Combination of Ethinylestradiol 20 mcg and Drospirenone 3 mg.
Bonassi Machado R; Pompei LM; Andrade R; Nahas E; Guazzelli C; Wender MC; Cruz AM
Int J Womens Health; 2020; 12():235-242. PubMed ID: 32280282
[TBL] [Abstract][Full Text] [Related]
34. A comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism.
van der Mooren MJ; Klipping C; van Aken B; Helmerhorst E; Spielmann D; Kluft C
Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():27-35. PubMed ID: 14677622
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of an oral contraceptive containing ethinylestradiol 20 µg/drospirenone 3 mg (24/4 regimen) in three indications in the People's Republic of China: a comparison with international studies.
Marr J; Huang Z; Wang B; Zhang H; Roth K
Open Access J Contracept; 2015; 6():95-104. PubMed ID: 29386927
[TBL] [Abstract][Full Text] [Related]
36. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers.
Oelkers W; Helmerhorst FM; Wuttke W; Heithecker R
Gynecol Endocrinol; 2000 Jun; 14(3):204-13. PubMed ID: 10923282
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate.
Vartiainen M; de Gezelle H; Broekmeulen CJ
Eur J Contracept Reprod Health Care; 2001 Mar; 6(1):46-53. PubMed ID: 11334476
[TBL] [Abstract][Full Text] [Related]
38. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
39. A comparative efficacy of low-dose combined oral contraceptives containing desogestrel and drospirenone in premenstrual symptoms.
Wichianpitaya J; Taneepanichskul S
Obstet Gynecol Int; 2013; 2013():487143. PubMed ID: 23577032
[TBL] [Abstract][Full Text] [Related]
40. Bioequivalence evaluation of a folate-supplemented oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium versus ethinylestradiol/drospirenone and levomefolate calcium alone.
Wiesinger H; Eydeler U; Richard F; Trummer D; Blode H; Rohde B; Diefenbach K
Clin Drug Investig; 2012 Oct; 32(10):673-84. PubMed ID: 22909145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
